Credit Currents - Moody's Ratings
Credit Currents - Moody's Ratings
Giulia Calcabrini, Chandra Ghosal, Patrick Ronk
Why Patent Cliffs Are Fueling Pharmaceutical M&A
10 minutes Posted Oct 1, 2026 at 12:00 pm.
0:00
10:33
Download MP3
Show notes
Pharma M&A is on track to exceed $160 billion this year, its highest level since before the pandemic. With $300 billion of revenue exposed to patent expirations over the next five years, drugmakers are turning to acquisitions to replenish pipelines and replace lost revenue. GLP-1 weight-loss drugs, along with oncology and neuroscience, key areas driving deal activity.